Open Access<p>Safety, Tolerability, and Pharmacokinetics of Adrenomedullin in Healthy Males: A Randomized, Double-Blind, Phase 1 Clinical Trial</p>
Author(s) -
Toshihiro Kita,
Yuichi Kaji,
Kazuo Kïtamura
Publication year - 2020
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s225220
Subject(s) - tolerability , medicine , pharmacokinetics , placebo , adverse effect , cmax , adrenomedullin , pharmacodynamics , dosing , contraindication , clinical trial , ulcerative colitis , pharmacology , anesthesia , gastroenterology , pathology , disease , alternative medicine , receptor
Adrenomedullin (AM), an endogenous vasodilative peptide, has immunomodulative effects and acts as an accelerator of mucosal regeneration in the digestive tract. AM has shown beneficial effects in rodent models of inflammatory bowel disease and patients with ulcerative colitis. The present study aimed to evaluate the pharmacodynamic properties and safety of AM in healthy male adults in a phase 1 clinical trial.